Cost effectiveness of budesonide/formoterol vs fluticasone/salmeterol: Real-world effectiveness and safety in COPD

被引：0
|
作者：
Hedegaard, Morten [1 ]
Janson, Christer [2 ]
Lisspers, Karin [3 ]
Stallberg, Bjorn [3 ]
Johansson, Gunnar [3 ]
Jorgensen, Leif [1 ]
Larssen, Kjell [4 ]
机构：
[1] Astrazeneca, R&D, Sodertalje, Sweden
[2] Uppsala Univ, Dept Med Sci, Resp Med, Uppsala, Sweden
[3] Uppsala Univ, Dept Publ Hlth & Caring Serv Family Med & Prevent, Uppsala, Sweden
[4] Karolinska Inst, Natl Inst Environm Med, Unit Lung & Allergy Res, Stockholm, Sweden
来源：
EUROPEAN RESPIRATORY JOURNAL | 2013年 / 42卷
关键词：
COPD; -; management; Exacerbation; Pneumonia;
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
1999
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A comparison of the cost-effectiveness of salmeterol/fluticasone combination inhaler and budesonide in the management of asthma
    Parnaby, A
    Lloyd, A
    Browning, D
    McCarthy, TP
    THORAX, 2000, 55 : A64 - A64
  • [22] Effectiveness and Treatment Compliance of Salmeterol–Fluticasone Easyhaler® Among Patients with Asthma, COPD, or Asthma–COPD Overlap Syndrome: Real-World Study Findings
    Lilla Tamási
    Anna Bartha
    Aranka Ferencz
    Mihály Tímár
    Mikko Vahteristo
    Aino Takala
    Veronika Müller
    Pulmonary Therapy, 2022, 8 : 369 - 384
  • [23] Patient inhaler satisfaction with Spiromax Budesonide/Formoterol versus Diskus Fluticasone/Salmeterol in COPD
    Van den Berge, Maarten
    Imkamp, Kai
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [24] Budesonide/formoterol maintenance and reliever therapy in childhood asthma: Real-world effectiveness and economic assessment
    Yu, Yuncui
    Cao, Wang
    Xiao, Yue
    Li, Ang
    Huang, Huijie
    Liu, Kejun
    Hu, Lihua
    Hou, Xiaoling
    Xiang, Li
    Wang, Xiaoling
    PEDIATRIC PULMONOLOGY, 2023, 58 (12) : 3406 - 3415
  • [25] Budesonide/Formoterol Maintenance and Reliever Therapy in Childhood Asthma: Real-World Effectiveness and Economic Assessment
    Lomonaco, Clarissa
    Dunn, Clinton
    PEDIATRICS, 2024, 154 : S50 - S50
  • [26] Real-world effectiveness of budesonide/ glycopyrrolate/formoterol in Chinese patients with chronic obstructive pulmonary disease
    Sun, Yongchang
    Chen, Yunfeng
    Zhang, Xiuwei
    Guo, Ruibin
    Zhou, Luqian
    Feng, Jiaxi
    Xiong, Xiaomin
    Xu, Weiguo
    Li, Guoping
    Zhang, Jing
    RESPIROLOGY, 2024, 29 : 156 - 156
  • [27] Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries
    Nielsen, Rune
    Kankaanranta, Hannu
    Bjermer, Leif
    Lange, Peter
    Arnetorp, Sofie
    Hedegaard, Morten
    Stenling, Anna
    Mittmann, Nicole
    RESPIRATORY MEDICINE, 2013, 107 (11) : 1709 - 1721
  • [28] Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting (vol 11, pg 2749, 2016)
    Perrone, V
    Sangiorgi, D.
    Buda, S.
    Degli Esposti, L.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2017, 12 : 227 - 227
  • [29] Cost-effectiveness analysis of budesonide/formoterol compared with fluticasone in moderate-persistent asthma
    Ericsson, K
    Bantje, TA
    Huber, RM
    Borg, S
    Bateman, ED
    RESPIRATORY MEDICINE, 2006, 100 (04) : 586 - 594
  • [30] Real-world study of formoterol/budesonide delivered through BAI in COPD patients
    Balamurugan, Santhalingam
    Pophale, Himanshu
    Samariya, Utsav
    Apte, Komalkirti
    Singh, Sheetu
    Dhar, Raja
    Rajan, Sujeet
    Swarnakar, Rajesh
    Talwar, Deepak
    Lopez, Meena
    Naik, Vaishali
    Sawant, Sandesh
    Chhowala, Sushmeeta
    Vaidya, Abhijit
    Gogtay, Jaideep
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
12345